Simcere Signs an Exclusive License Agreement with JW Pharmaceutical for an Anti-Gout Drug Candidate URC-102 in China

Shots:

• JWP to receive up front, commercial milestones & royalties on sales in China.  Simcere to get the license for clinical research, registration, and commercialization of URC-102 in China (including Hongkong & Macao)
• The collaboration will combine JWP’s expertise in new molecular entity drug discovery & development with Simcere expertise in clinical development and commercialization of therapies for rheumatic diseases
• URC-102 is a selective uric acid transporter (URAT-1) inhibitor, currently being evaluated in P-IIb for patients with gout in South Korea

Click here to­ read full press release/ article | Ref: PRNewswire | Image: TicaChina